The Evaluation of Astaxanthin Effects on Differentiation of Human Adipose Derived Stem Cells into Oligodendrocyte Precursor Cells

Nazem Ghasemi

Department of Anatomical Science and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Multiple Sclerosis (MS) has been explained as an autoimmune mediated disorder in central nerve system. Since conventional therapies for MS are not able to stop or reverse the destruction of nerve tissue, stem cell-based therapy has been proposed for the treatment of MS. Astaxanthin (AST) is a red fat-soluble xanthophyll with neuroprotection activity. The aim of this study was evaluation of pre-inducer function of AST on differentiation of human Adipose-Derived Stem Cells (hADSCs) into oligodendrocyte precursor cells.

Methods: After stem cell isolation, culture and characterization by flow cytometry, hanging drop technique was done for embryoid body formation. In the following, hADSCs were differentiated into oligodendrocyte cells in the presence of AST at various concentrations (1, 5, and 10 ng/ml). Finally, immunocytochemistry and real-time PCR techniques were used for assessment of oligodendrocyte differentiation.

Results: Flow cytometry results indicated that hADSCs were CD44, CD49-positive, but were negative for CD14, CD45 markers. In addition, immunocytochemistry results revealed that, in AST treated groups, the mean percentage of Olig 2 and A2B5 positive cells increased especially in 5 ng/ml AST treated group compared to control group (p<0.001). Moreover, real-time PCR analysis confirmed the results of immunocytochemistry.

Conclusion: Since hADSCs have the potential to differentiate into multi lineage cells and due to important functions of AST in regulating various cellular processes, it seems that AST can be used as a promoter for oligodendrocyte differentiation of hADSCs for being used in cell transplantation in multiple sclerosis.

Keywords: Adult stem cells, Astaxanthin, Multiple sclerosis, Oligodendroglia

Introduction

Multiple Sclerosis (MS) has been explained as an autoimmune-mediated disorder which is characterized by central nervous system lesions. This abnormal condition can develop a complex pattern of physical or cognitive disability as well as neurological defects ¹. Unfortunately, the exact etiology of MS remains unclear. In spite of this, genetic predispositions, together with environmental factors such as exposure to infectious agents, vitamin D deficiencies and smoking have a major role in MS development ² ⁵. Meanwhile, multifocal zones of inflammation due to immune cell infiltrations and oligodendrocyte death can trigger a cascade of events which lead to nerve demyelination ⁶. As a result, the myelin sheath destruction and astrogliosis formation occurs in both white and gray matters which can interfere with correct transmission of nerve impulse and lead to neuronal dysfunction.

Since conventional therapies for MS are not able to stop or reverse the destruction of nerve tissue, stem cell-based therapy has been proposed for the treatment of neurodegenerative diseases ⁷ ⁸. In previous studies, human embryonic stem cells, human bone-marrow-derived MSCs and human placental mesenchymal stem cells were transplanted in animal models of MS. According to the result of these studies, the main mechanisms responsible for these therapeutic effects are related to neurotrophic function and differentiation potential of stem cells ⁷ ⁹ ¹⁰. Other experiments demonstrated that human dental pulp stem cells and Wharton’s jelly stem cells are able to differentiate into oligodendrocyte precursor cells ¹¹ ¹². In addition, these cells are able to promote the remyelination process and significantly decrease the clinical signs of MS when transplanted in animal model of MS.
Human Adipose-Derived Stem Cells (hADSCs) are a kind of adult stem cells which have specific features including immunomodulatory and neuroprotective effects. In addition, these cells are able to differentiate into other cells outside their lineage and can be used to cell transplantation in animal models of MS 7,13.

Despite the beneficial effects of stem cell transplantation, the serious adverse events of this manner such as tumorigenic potential should not be denied. Thus, cell transplantation using differentiated cells may decrease serious adverse complications of stem cell therapy. To this end, molecular pathways and their ligands as well as neuroprotective factors which are involved in stem cell differentiation have been studied for having access to a homogeneous population of differentiated cells.

Astaxanthin (AST) (3, 3'-dihydroxy-β, β'-carotene-4, 4'-dione) is a red fat-soluble xanthophyll that is found in various microorganisms 14. This pigment in comparison to other carotenoids can prevent or reduce the risk of various human abnormalities such as neurodegenerative diseases 15,16. AST due to special molecular structure can be connected to cell membrane and exhibit several biological activities than other antioxidants 17. It has been reported that AST has significant effects on immune function both in vitro and in vivo 18,19. For example, AST can improve immune cell proliferation and reduce humoral immune response and increase immunoglobulin production 20,21.

According to previous published data, AST is used as a promising agent for treatment of inflammation due to protective effects against inflammation and apoptosis in epithelial cells 22. In addition to the above mentioned effects of AST, this agent also has other effects including neuroprotection activity 23, anti-lipid peroxidation 24, and anticancer activity 25. Due to the broad biological activity of AST, in this study, the pre-inducer function of AST on differentiation of hADSCs into oligodendrocyte progenitor cells was assessed.

**Materials and Methods**

**Isolation and culture of hADSCs**

All other chemicals, unless specified otherwise, were prepared from Sigma-Aldrich, St. Louis, MO, USA. Meanwhile, all procedures were approved by the Ethics Committee of Isfahan University of Medical Sciences (ethical code: 194267). After receiving informed consent of patients who admitted to Al-Zahra Hospital (Isfahan, Iran), hADSCs were isolated from human abdominal fat that were collected from lipoaspirate samples of three female donors (age range: 20-40 years) and cultured. According to a previous study 26, the obtained samples were washed extensively with Phosphate-Buffer Saline (PBS) in order to remove contaminating debris and then carefully dissected and minced. Following that, the samples were enzymatically dissociated for 30 min at 37°C using 0.075% collagenase type I (Invitrogen, UK). After this period, this solution was neutralized with an equal volume of Dulbecco’s Modified Eagles Medium (DMEM/F12) ( Gibco BRL, Paisley, UK) supplemented with 10% Fetal Bovine Serum (FBS) (Gibco) and then centrifuged for 10 min at 1200 g. The cellular pellet was resuspended in DMEM/F12, 10% FBS and 1% penicillin/streptomycin solution and was cultured in 25 cm² flasks for 4-5 days until they reached approximately 90% confluence in a 37°C humidified incubator with a 5% CO₂ environment.

**Cell surface marker characterization**

Flow cytometric analysis was used for investigating the cell surface markers according to previous study 27. For this purpose, 10×10⁶ hADSCs were collected from passage 3 cultures and washed twice with PBS. After removing the supernatant, the cell pellet was incubated with respective fluorochrome-conjugated antibodies against CD14, CD44, CD45 and CD90 (3 µl/10⁶ cells) (Chemicon, Temecula, CA, USA) for 30 min on ice. In addition, for isotype control, non-specific FITC-conjugated IgG was substituted for the primary antibodies. After incubation, the cells were washed with PBS and after centrifuging (800×g for 5 min), cell pellet was resuspended in 500 µl of solution buffer and was transferred to flow cytometry tubes. Finally, the percentages of fluorescent cells were analyzed by a flow cytometer (Becton Dickinson, San Jose, CA).

**Hanging drop technique**

For embryoid body formation, 1×10⁶ hADSCs in 15 µl DMEM/F12 supplemented with 2% B27, 20 ng/ml Human Epidermal Growth Factor (H-EGF), 20 ng/ml human basic Fibroblast Growth Factor (hbFGF) suspended on the inner side of tissue culture dishes were cultured for 48 hr under standard conditions. After this time, the embryoid bodies were collected and were split in single cells and were cultured for 4 days under standard conditions in the previous medium.

**Induction of oligodendrocyte differentiation**

After cell confluency, hADSCs were dissociated using Trypsin/EDTA and seeded at 1×10⁶ cells/cm² on 24 well TC plates (coated with 0.1 mg/ml poly-D-lysine) and were cultured in a pre-differentiation medium consisting of DMEM/F12, 1×NEAA, L-glutamine (2 mM), 1×N2, 1×B27, Shh (200 ng/ml), retinoic acid (2 µM) and different concentrations (1, 5 and 10 ng/ml) of AST. After 10 days, the pre-differentiation medium was replaced with DMEM/F12, 1×NEAA, L-glutamine (2 mM), 1×N2, 1×B27, NT3 (30 ng/ml), Platelet-Derived Growth Factor alpha (PDGFα) (10 ng/ml) and different concentrations (1, 3 and 10 ng/ml) of AST for 2 weeks. Meanwhile, the control group cells were differentiated in differentiation medium similar to other groups but in the absence of AST.

**Immunocytochemistry technique**

In the following oligodendrocyte differentiation, differentiated cells were fixed with 4% Paraformaldehyde (PFA) for 15 min at room temperature, incubated in 1%
BSA/10% normal goat serum/0.3 M glycine in 0.1% PBS-Tween for 1 hr to permeabilise the cells and block non-specific protein-protein interactions. In the following, incubation with primary antibodies diluted in PBS with 0.1% BSA, overnight at 4°C in humidified condition was done. The following antibodies were used: anti-A2B5 antibody, 1 µg/ml; Abcam; anti-olig2 antibody, 1:1000; Abcam. After cell washing, the slides were treated with goat anti-mouse FITC (1:500; Abcam, UK)-conjugated secondary antibodies diluted in PBS with 0.1% BSA at RT for 1 hr. After this time, cells were washed and fixed with 4% PFA for 5 min at room temperature. Finally, the nuclei were stained with DAPI for cell counting using fluorescence microscope (Olympus, BX51, Japan). For quantitative analysis, the number of A2B5, olig2 positive cells was counted on each acquired image in a minimum total of 200 cells per slide.

**Real-time PCR**

In order to evaluate gene expression, total RNA was extracted from 1×10⁵ differentiated and non-differentiated cells using RNeasy micro Kit (Qiagen) according to previous study 28. After RNA dissolving in DEPC-treated water, cDNA synthesis was done using RevertAid First Strand cDNA Synthesis Kit (Fermentas, Germany). According to the manufacturer’s instructions, 2 µg of RNA was used for cDNA synthesis. Finally, quantitative real-time PCR was done using Thermal Cycler Rotor-Gene in a total volume of 20 µl containing Power SYBR Green master mix (2x), forward and reverse Primers (0.5 µM), cDNA (30 ng/µl) and H2O. At the end of this procedure, the mRNA expressions were measured for Olig2, PDGFRα (specific oligodendrocyte precursor genes), astrocyte specific marker (GFAP) and a housekeeping gene (GAPDH). Meanwhile, the sequences of all primers are presented in table 1.

**Statistical analysis**

For data analysis, independent sample t-test and one-way analysis of variance (ANOVA) were used. Data are presented as mean±SEM and to determine the statistical significance between data, p<0.05 was considered to be statistically significant. Meanwhile, all experimental procedures were repeated at least three times.

Table 1. Primer sequences used for real-time PCR analysis

| Gene primers | sequence |
|--------------|----------|
| Olig2        | F: 5'-CGCAGCGGACCTCCAAAATCTAA-3' |
|              | R: 5'-CCCAGGGATGATCTAAGCTCTCGAA-3' |
| PDGFRα       | F: 5'- GTG GGA CAT TCA TTG CGG A-3' |
|              | Rev: 5' AAG CTG GCA GAG GAT TAG G-3' |
| GFAP         | F: 5'- CCGACAGCGGACCTCCAAAATCTAA-3' |
|              | Rev: 5'-GTGCGACAGCGGACCTCCAAAATCTAA-3' |
| GAPDH        | F: 5'-GAGCCCGCGGCTCCGG-3' |
|              | Rev: 5'-GAGCCCGCGGCTCCGG-3' |

**Results**

**HADSCs and oligodendrocyte characterization**

As shown in figure 1A, hADSCs in primary culture exhibited fibroblast-like morphology. After hanging drop, the cells were aggregated and composed embryoid bodies (Figure 1B). Moreover, in the end-stage of differentiation, multipolar morphology with extensive processes was seen in differentiated cells (satellite-like morphology) (Figure 1C). In addition, flow cytometry analysis of hADSCs within passage 3 showed that hADSCs were CD44 and CD90 positive, but were negative for CD14, CD45 (hematopoietic markers) (Figure 2).

**Immunocytochemistry study of differentiated cells**

Immunocytochemistry staining with cell type specific markers was used to identify the phenotypes of differentiated cells (Figures 3 and 4). Fluorescence microscopic analysis revealed that the mean percentage of olig 2 positive cells increased in all AST treated groups especially in 5 ng/ml AST treated group in comparison to control group (p<0.001) (Figure 5).

**Real-time PCR results**

After RNA extraction from differentiated cells, real-time PCR assay was done. To this end, GAPDH was used as a control marker. Finally, our results revealed that the expression of Olig2 and PDGFRα markers (oligodendrocyte precursor markers) were higher in comparison to control group which is consistent with the results of immunocytochemistry (Figure 6). In addition, the GFAP expression was low which suggests...
that the differentiation of hADSCs into oligodendrocyte cells was favorable.

**Discussion**

MS is one of the most autoimmune-mediated disorders which is usually detected in young adults. Due to progressive myelin destruction which is created during this abnormal condition, severe physical or cognitive disabilities as well as neurological problems can occur. The formation of CNS plaques as a result of focal immune cells infiltration is the primary cause of damage in MS. Thus, the conventional therapy for MS is based on the use of immunosuppressive agents. Since this strategy can’t suppress the MS progression, cell-based therapy has been suggested for the treatment of this pathological condition.

Adipose Derived Stem Cells (ADSCs) due to their special characteristics such as the ability to differentiate into oligodendrocyte cells can be used for cell-based therapy in MS. These cells via production of several growth factors such as nerve growth factor and brain-derived neurotrophic factor as well as myelin shell components have a significant role in remyelination and maintenance of the CNS functions. In our previous study, hADSCs were transplanted in lysolecithin model of MS. The results of this study revealed that hADSCs are able to differentiate into oligodendrocytes and improve remyelination process and motor functions may improve.

Unlike these studies which offered the beneficial potential of stem cell therapy, the serious adverse events of this method such as tumorigenic potential cannot be denied. Thus, transplantation of differentiated cell instead of stem cells may be a safe procedure. In vitro stem cell differentiation can be done using several promoting factors such as nerve growth factors and antioxidants. Thus, in this study, pre-inducer function of AST was assessed on differentiation of hADSCs into oligodendrocyte progenitor cells.

As shown in figure 1B, hADSCs were aggregated after hanging drop and composed embryoid bodies. Hanging drop because of providing a three-dimensional...
micro-environmental niche for cells can facilitate the cell differentiation via providing direct interaction among cell population. Another relevant finding of our study was that AST is able to induce the expression of Olig2 and A2B5 markers (oligodendrocyte progenitor’s cells) in a dose-dependent manner (Figures 3 and 4). In particular, 5 ng/ml AST administered revealed the highest effects on hADSCs differentiation. Thus, 5 ng/ml AST applied was determined to be the optimal treatment for studying hADSCs differentiation into oligodendrocytes. In addition, the results of real-time PCR revealed that differentiated cells expressed oligodendrocyte precursor markers in high level which is consistent with the results of immunocytochemistry (Figure 6). Moreover, the expression of GFAP gene was in low level in all AST treated groups (especially in 5 ng/ml AST treated group) revealing the highest protective effects on gene expression is able to promote the expression of GFAP gene was in low level in all AST treated groups (especially in 5 ng/ml AST treated group) revealing the highest protective effects on endogenous repair in animal models of multiple sclerosis. Stem Cells 2014;27(10):2624-2635.

6. Sharp J, Frame J, Siegenthaler M, Nistor G, Keirstead HS. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. Stem Cells 2010;28(1):152-163.

7. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2014;56(5):470-478.

8. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2014;56(5):470-478.

9. Askari N, Yaghoobi MM, Shamsara M, Esmaili-Mahani S. Human dental pulp stem cells differentiate into oligodendrocyte progenitors using the expression of Olig2 transcription factor. Cells Tissues Organs 2015;200(2):163.

10. Mikaeili Agah E, Parivar K, Joghataei MT. Therapeutic effect of transplanted human Wharton’s jelly stem cell-derived oligodendrocyte progenitor cells (hWJ-MSC-derived OPCs) in an animal model of multiple sclerosis. Mol Neurobiol 2014;49(2):625-632.

11. GhaseMI N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J 2017;19(1):1-10.

12. Sadovnick AD, Ebers GC, Dymant DA, Risch NJ. Evidence for genetic basis of multiple sclerosis. The Canadian collaborative study group. Lancet 1996;347(9017):1728-1730.

13. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006;19(1):80-94.

14. O’Gorman C, Bukhari W, Todd A, Freeman S, Broadley SA. Smoking increases the risk of multiple sclerosis in Queensland, Australia. J Clin Neurosci 2014;21(10):1730-1733.

15. Speer G. [Impact of vitamin D in neurological diseases and neurorehabilitation: from dementia to multiple sclerosis. Part I: the role of vitamin D in the prevention and treatment of multiple sclerosis]. Idegyogy Sz 2013;66(9-10):293-303. Hungarian.

16. Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropsychiatry 2011;9(3):409-416.

17. GhaseMI N, Razavi S, Mardani M, Esfandiari E, Salehi H, Zarkesh Esfahani SH. Transplantation of human adipose-derived stem cells enhances remyelination in lysolecithin-induced focal demyelination of rat spinal cord. Mol Biotechnol 2014;56(5):470-478.

18. Ghasemi N, Razavi S, Nikzad E, Salehi H. Improvement of myelin remyelination after transplantation of human adipose tissue-derived stem cell in rat multiple sclerosis model. J Isfahan Med School 2016;33(366):2333-2340.

Avicenna Journal of Medical Biotechnology, Vol. 10, No. 2, April-June 2018

Figure 6. Comparative analysis of Olig2, PDGFRα and GFAP markers using real time RT-PCR. Quantification was done in oligodendrocytes after normalization to GAPDH. The expression levels of Olig2 and PDGFRα increased significantly in 5 ng/ml AST treated group compared to control group (p<0.05).

Conclusion

The results of this study indicate that AST via protective effects on gene expression is able to promote the differentiation of hADSCs into oligodendrocyte progenitor cells. So, AST has beneficial therapeutic effects for cell therapy in the treatment of neurodegenerative diseases such as MS.

Acknowledgement

The author is grateful to Isfahan University of Medical Sciences for financial support (Grant number. 194267).

References

1. Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J 2017;19(1):1-10.

2. Sadovnick AD, Ebers GC, Dymant DA, Risch NJ. Evidence for genetic basis of multiple sclerosis. The Canadian collaborative study group. Lancet 1996;347(9017):1728-1730.

3. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006;19(1):80-94.

4. O’Gorman C, Bukhari W, Todd A, Freeman S, Broadley SA. Smoking increases the risk of multiple sclerosis in Queensland, Australia. J Clin Neurosci 2014;21(10):1730-1733.

5. Speer G. [Impact of vitamin D in neurological diseases and neurorehabilitation: from dementia to multiple sclerosis. Part I: the role of vitamin D in the prevention and treatment of multiple sclerosis]. Idegyogy Sz 2013;66(9-10):293-303. Hungarian.

6. Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropsychiatry 2011;9(3):409-416.

7. GhaseMI N, Razavi S, Mardani M, Esfandiari E, Salehi H, Zarkesh Esfahani SH. Transplantation of human adipose-derived stem cells enhances remyelination in lysolecithin-induced focal demyelination of rat spinal cord. Mol Biotechnol 2014;56(5):470-478.

8. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009;27(10):2624-2635.

9. Sharp J, Frame J, Siegenthaler M, Nistor G, Keirstead HS. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. Stem Cells 2010;28(1):152-163.

10. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009;57(11):1192-1203.

11. Askari N, Yaghoobi MM, Shamsara M, Esmaili-Mahani S. Human dental pulp stem cells differentiate into oligodendrocyte progenitors using the expression of Olig2 transcription factor. Cells Tissues Organs 2017;19(1):1-10.

12. Mikaeili Agah E, Parivar K, Joghataei MT. Therapeutic effect of transplanted human Wharton’s jelly stem cell-derived oligodendrocyte progenitor cells (hWJ-MSC-derived OPCs) in an animal model of multiple sclerosis. Mol Neurobiol 2014;49(2):625-632.

13. GhaseMI N, Razavi Sh, Salehi H. Improvement of myelin ultrastructure after transplantation of human adipose tissue-derived stem cell in rat multiple sclerosis model. J Isfahan Med School 2016;33(366):2333-2340.
14. Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr 2006;46:185-196.

15. Kidd P. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Altern Med Rev 2011;16:355-364.

16. Guerin M, Huntley ME, Olaizola M. Haematococcus astaxanthin: applications for human health and nutrition. Trends Biotechnol 2003;21:210-216.

17. Yuan JP, Peng J, Yin K, Wang JH. Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae. Mol Nutr Food Res 2011;55:150-165.

18. Rao AR, Baskaran V, Sarada R, Ravishankar GA. In vivo bioavailability and antioxidant activity of carotenoids from microalgal biomass-a repeated dose study. Food Res Int 2013;54(1):711-717.

19. Ranga Rao A, Raghunath Reddy RL, Baskaran V, Sarada R, Ravishankar GA. Characterization of microalgal carotenoids by mass spectrometry and their bioavailability and antioxidant properties elucidated in rat model. J Agric Food Chem 2010;58(15):8553-8559.

20. Jyonouchi H, Sun S, Gross M. Effect of carotenoids on in vitro immunoglobulin production by human peripheral blood mononuclear cells: astaxanthin, a carotenoid without vitamin a activity, enhances in vitro immunoglobulin production in response to ad-pendent stimulant and antigen. Nutr Cancer 1995;23:171-183.

21. Park JS, Mathison BD, Hayek MG, Massimino S, Reinhart GA, Chew BP. Astaxanthin stimulates cell-mediated and humoral immune responses in cats. Vet Immunol Immunopathol 2011;144(3-4):455-4561.

22. Suzuki Y, Ohgami K, Shiratori K, Jin XH, Ilieva I, Koyama Y, et al. Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-kappaB signaling pathway. Exp Eye Res 2006;82(2):275-281.

23. Lu YP, Liu SY, Sun H, Wu XM, Li JJ, Zhu L. Neuro-protective effect of astaxanthin on H2O2-induced neurotoxicity in vitro and on focal cerebral ischemia in vivo. Brain Res 2010;1360:40-48.

24. Kamath BS, Srivanta BM, Dharmesh SM, Sarada R, Ravishankar GA. Ulcer preventive and antioxidative properties of astaxanthin from Haematococcus pluvialis. Eur J Pharmocol 2008;590(1-3):387-395.

25. Fathi E, Farahzadi R, Charoudeh HN. L-carnitine contributes to enhancement of neurogenesis from mesenchymal stem cells through Wnt/beta-catenin and PKA pathway. Exp Biol Med (Maywood) 2017;242(5):482-486.

26. Mobarak H, Fathi E, Farahzadi R, Zarghami N, Javanmardi S. L-carnitine significantly decreased aging of rat adipose tissue-derived mesenchymal stem cells. Vet Res Commun 2016;41(1):41-47.

27. Fathi E, Farahzadi R. Enhancement of osteogenic differentiation of rat adipose tissue-derived mesenchymal stem cells by zinc sulphate under electromagnetic field via the PKA, ERK1/2 and Wnt/beta-catenin signaling pathways. PloS one 2017;12(3):e0173877.

28. Chew BP, Park JS, Wong MW, Wong TS. A comparison of the anticancer activities of dietary beta-carotene, canthaxanthin and astaxanthin in mice in vivo. Anticancer Res 1999;19(3A):1849-1853.

29. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006;2(4):201-211.

30. Li A, Liu X, Duan B, Ma J. Thymic nurse cells support CD4^CD8^thymocytes to differentiate into CD4^CD8^ cells. Cell Mol Immunol 2005;2(4):301-305.

31. Nakagawa Y, Ohigashi I, Nitta T, Sakata M, Tanaka K, Murata S, et al. Thymic nurse cells provide microenvironment for secondary T cell receptor alpha rearrangement in cortical thymocytes. Proc Natl Acad Sci USA 2012;109(50):20572-20577.